↑ 疾患リストへ ← 戻る

 226. 間質性膀胱炎(ハンナ型) [臨床試験数:83,薬物数:122(DrugBank:44),標的遺伝子数:54,標的パスウェイ数:134] 

Searched query = "Interstitial cystitis with Hunners ulcer", "Interstitial cystitis"
The queries were searched in Public_title, Scientific_title, and Condition of the data. Export date: 11/20/2019, 11/21/2019. Trials are sorted by Date_enrolment from most recent to oldest in the table.

Search in Page    e.g. "Phase 3", "Not recruiting", "Japan"    Synonyms (DrugBank) were also searched for.
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03844412July 12, 201926 August 2019Vestibulodynia: Understanding Pathophysiology and Determining Appropriate TreatmentsVestibulodynia: Understanding Pathophysiology and Determining Appropriate TreatmentsVestibulodynia;Temporomandibular Disorder;Fibromyalgia Syndrome;Irritable Bowel Syndrome;Migraines;Tension Headache;Endometriosis;Interstitial Cystitis;Back Pain;Chronic Fatigue SyndromeDrug: 5% lidocaine/5 mg/ml estradiol compound cream;Drug: Nortriptyline;Drug: Placebo cream;Drug: Placebo pillDuke UniversityEunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)Recruiting18 Years50 YearsFemale400Phase 2United States
2NCT04118946March 20, 201922 October 2019Platelet Enriched Plasma for Treatment of Interstitial CystitisIntra Vesical Instillation Versus Submucosal Injection of Platelet Enriched Plasma for Treatment of Interstitial Cystitis/Bladder Pain Syndrome: A Randomized Controlled TrialInterstitial Cystitis;Bladder Pain Syndrome;Platelet Enriched PlasmaBiological: platelet enriched plasmaMansoura UniversityRecruiting18 YearsN/AFemale33Phase 1/Phase 2Egypt
3NCT03463915January 25, 201918 March 2019Clinical Trial Comparing Two Bladder Instillations for IC/BPSRandomized Controlled Trial Comparing Two Different Bladder Instillation Treatments for Interstitial Cystitis/Bladder Pain SyndromeInterstitial Cystitis;Bladder Pain SyndromeDrug: Bladder instillation WITH triamcinolone acetonide;Drug: Bladder instillation WITHOUT triamcinolone acetonideOlivia Cardenas-Trowers, M.D.Recruiting18 YearsN/AFemale80Phase 3United States
4NCT03844581January 1, 20194 March 2019Effect of Interferential Electrical Stimulation on Pain Perception and Disability Level on Interstitial CystitisEffect of Interferential Electrical Stimulation on Pain Perception and Disability Level on Interstitial CystitisInterstitial CystitisDevice: interferential current;Drug: Propiverine HydrochlorideCairo UniversityNot recruiting25 Years40 YearsFemale40N/AEgypt
5NCT03143920November 1, 201726 November 2018Hyperbaric Oxygen Therapy for Inflammatory Conditions of the Urinary BladderHyperbaric Oxygen Therapy for Inflammatory Conditions of the Urinary Bladder: A Feasibility TrialChronic Interstitial Cystitis;Painful Bladder Syndrome;Recurrent Urinary Tract InfectionCombination Product: Hyperbaric Oxygen Therapy-University of California, San DiegoRecruiting35 Years70 YearsFemale40Early Phase 1United States
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6JPRN-UMIN0000291132017/10/102 April 2019Clinical study on the effect of fermented buckwheat sprouts in patients with interstitial cystitisPatients with interstitial cystitisIngestion of test food including fermented buckwheat sprouts (12 weeks, 4 tablets / once a day)Center for Pharma-Food Research, Graduate School of Pharmaceutical Sciences, University of ShizuokaKageyama Hospital (Shizuoka city) Nakamura Hospital (Beppu city)Not Recruiting20years-oldNot applicableMale and Female20Not selectedJapan
7NCT03282318September 28, 201711 June 2019A Study to Investigate Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of ASP6294 in the Treatment of Female Subjects With Bladder Pain Syndrome/Interstitial CystitisA Phase 2a, Randomized, Double-blind, Placebo-controlled, Parallel-group, Proof of Concept Study to Investigate Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of ASP6294 in the Treatment of Female Subjects With Bladder Pain Syndrome/Interstitial CystitisBladder Pain Syndrome;Interstitial CystitisDrug: Placebo;Drug: ASP6294Astellas Pharma Europe B.V.Not recruiting18 YearsN/AFemale117Phase 2Belgium;Czechia;Germany;Hungary;Latvia;Netherlands;Poland;Russian Federation;Spain;United Kingdom
8EUCTR2016-004138-12-DE26/09/201719 November 2018Study of the effect of ASP6294 for the treatment of Bladder Pain Syndrome/Interstitial Cystitis in female subjects.A Phase 2a, Randomized, Double-blind, Placebo-controlled, Parallel-group, Proof of Concept Study to Investigate Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of ASP6294 in the Treatment of Female Subjects with Bladder Pain Syndrome/Interstitial CystitisBladder Pain Syndrome/Interstitial Cystitis (BPC/IC)
MedDRA version: 20.0 Level: LLT Classification code 10071166 Term: Bladder pain syndrome System Organ Class: 100000004857 ;Therapeutic area: Diseases [C] - Female diseases of the urinary and reproductive systems and pregancy complications [C13]
Product Name: ASP6294
Pharmaceutical Form: Solution for injection
INN or Proposed INN: Not applicable
Current Sponsor code: ASP6294
Other descriptive name: ASP6294
Concentration unit: mg/ml milligram(s)/millilitre
Concentration type: equal
Concentration number: 40-
Pharmaceutical form of the placebo: Solution for injection
Route of administration of the placebo: Subcutaneous use
Astellas Pharma Europe B.V.AuthorisedFemale: yes
Male: no
163Phase 2Hungary;Czech Republic;Poland;Belgium;Spain;Russian Federation;Netherlands;Latvia;Germany;United Kingdom
9NCT03463499September 22, 201723 April 2019The Efficacy and Safety of Intravesical Hyaluronic Acid and Chondroitin Sulfate After Transurethral Resection of Hunner Lesion in Interstitial Cystitis/Bladder Pain Syndrome PatientsThe Efficacy and Safety of Intravesical Hyaluronic Acid and Chondroitin Sulfate After Transurethral Resection of Hunner Lesion in Interstitial Cystitis/Bladder Pain Syndrome PatientsInterstitial CystitisDrug: Hyaluronic Acid and Chondroitin SulfateSamsung Medical CenterRecruiting20 YearsN/AAll62N/AKorea, Republic of
10JPRN-JapicCTI-17356625/5/201716 July 2019Phase III study of KRP-116DA Phase III, multicenter, randomized, double-blind, placebo controlled, parallel group study to assess the efficacy and safety of KRP-116D in Japanese patients with interstitial cystisis.Interstitial cystitis( IC )Intervention name : KRP-116D
INN of the intervention : dimethyl sulfoxide
Dosage And administration of the intervention : 50 mL intravesical instillation once every two weeks
Control intervention name : Placebo
INN of the control intervention : -
Dosage And administration of the control intervention : 50 mL intravesical instillation once every two weeks
Kyorin Pharmaceutical Co.,LTDNot Recruiting20BOTH90Phase 3Japan
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
11NCT02870738April 21, 201730 September 2019Bladder Directed vs. Pelvic Floor Therapy in IC/BPSComparison of Bladder Directed and Pelvic Floor Therapy in Women With Interstitial Cystitis/Bladder Pain SyndromeCystitis, Interstitial;Painful Bladder SyndromeProcedure: Pelvic Floor Physical Therapy;Drug: Bladder InstillationsWilliam Beaumont HospitalsBaylor College of MedicineRecruiting18 Years85 YearsFemale128Phase 2United States
12NCT03104361April 201716 December 2017Platelet-Rich Plasma (PRP) Injection in Treatment of Interstitial CystitisIntravesical Injections of Platelet-Rich Plasma (PRP) in Treatment of Interstitial Cystitis Refractory to Conventional Treatment - A Prospective, Clinical TrialInterstitial CystitisBiological: Platelet-Rich PlasmaBuddhist Tzu Chi General HospitalNot recruiting20 YearsN/AAll30Phase 1Taiwan
13NCT03008382March 1, 201729 July 2019Interstitial Cystitis: Examination of the Central Autonomic NetworkInterstitial Cystitis: Examination of the Central Autonomic NetworkInterstitial Cystitis/Painful Bladder Syndrome;Myofascial Pelvic PainDrug: Metoprolol Tartrate Oral Tablet;Drug: Placebo Oral TabletMedical College of WisconsinNorthShore University HealthSystem;Case Western Reserve UniversityRecruiting18 Years80 YearsFemale180Phase 4United States
14NCT02787083August 201614 October 2019A Pilot Study of the Effects of Mirabegron on Symptoms in Patients With Interstitial CystitisA Pilot Study of the Effects of Mirabegron on Symptoms in Patients With Interstitial CystitisCystitis, InterstitialDrug: Mirabegron;Drug: PlaceboPhiladelphia Urosurgical AssociatesAstellas Pharma Global Development, Inc.Not recruiting18 Years95 YearsFemale9Phase 3United States
15JPRN-UMIN0000279182016/07/012 April 2019Heparin-lidocaine intravesical injection therapy for refractory interstitial cystitisinterstitial cystitisheparin-lidocaine intravesical therapyDepartment of Urology and Renal transplantation, Nagasaki University HospitalRecruiting20years-old80years-oldMale and Female30Not selectedJapan
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
16NCT02858453July 201611 June 2018Efficacy and Safety of 2 Doses of AQX-1125 in Subjects With Interstitial Cystitis / Bladder Pain SyndromeThe LEADERSHIP 301 Trial: A 12-Week, Randomized, Multi-Center, Double-Blind, Placebo-Controlled, 3-Arm, Parallel-Group, Phase 3 Trial to Evaluate the Efficacy and Safety of 2 Doses of AQX-1125 Targeting the Src Homology 2-containing Inositol-5'-Phosphatase 1 (SHIP1) Pathway in Subjects With Interstitial Cystitis/Bladder Pain Syndrome Followed by an Extension PeriodInterstitial Cystitis;Bladder Pain Syndrome;Painful Bladder Syndrome;Chronic Interstitial CystitisDrug: AQX-1125 100 mg;Drug: AQX-1125 200 mg;Drug: PlaceboAquinox Pharmaceuticals (Canada) Inc.Not recruiting18 Years80 YearsAll433Phase 3United States;Belgium;Canada;Czechia;Denmark;Hungary;Latvia;Netherlands;Poland;Romania;Spain;United Kingdom;Czech Republic
17NCT03693001June 1, 20169 October 2018HBOT for Patients With IC/FM (Interstitial Cystitis/Fibromyalgia)Clinical and Morphological Effects of Hyperbaric Oxygen Therapy in Patients With Interstitial Cystitis Associated With FibromyalgiaFibromyalgia;Interstitial CystitisDevice: Intermittent Exposure to Oxygen via Oro-Nasal MaskUniversity of South FloridaUniversity of PadovaNot recruiting18 YearsN/AAll12N/A
18JPRN-UMIN0000267142016/02/262 April 2019RCT study of bladder instillation therapy in patients with refractory interstitial cystitis.Interstitial cystitisTreated with vesical instillation with heparin and alkalized lidocaine. As introduction therapy, patients will recieve instillation every 1 to 2 weeks for six times. Then maintenance therapy follows with 6 times of monthly instillation.
Treated with vesical instillation with heparin alone. As introduction therapy, patients will recieve instillation every 1 to 2 weeks for six times. Then maintenance therapy follows with 6 times of monthly instillation.
Department of Urology, Mitsui Memorial HospitalNot Recruiting20years-oldNot applicableMale and Female20Phase 2,3Japan
19NCT02497976December 15, 201511 June 2018Pilot Study Evaluating the Efficacy of Certolizumab Pegol for Interstitial CystitisPilot Study Evaluating the Efficacy of Certolizumab Pegol for Interstitial CystitisCystitis, InterstitialBiological: Certolizumab pegol;Drug: PlaceboICStudy, LLCUCB PharmaNot recruiting18 Years65 YearsFemale42Phase 3United States
20EUCTR2015-004495-30-FI14/12/201528 December 2015Safety of intravesical bladder instillations among patients with severe interstitial cystitisSafety of intravesical bladder instillations among patients with severe interstitial cystitisInterstitial cystitis and bladder pain syndrome
MedDRA version: 18.1 Level: LLT Classification code 10071166 Term: Bladder pain syndrome System Organ Class: 10038359 - Renal and urinary disorders
MedDRA version: 18.1 Level: PT Classification code 10011796 Term: Cystitis interstitial System Organ Class: 10038359 - Renal and urinary disorders ;Therapeutic area: Diseases [C] - Male diseases of the urinary and reproductive systems [C12]
Trade Name: SANDIMMUN
Pharmaceutical Form: Concentrate for solution for infusion
INN or Proposed INN: CICLOSPORIN
CAS Number: 59865-13-3
Oulu University HospitalAuthorisedFemale: yes
Male: yes
Finland
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
21NCT02591199September 201523 July 2018Engage 24: Evaluation of the Safety and Effectiveness of URG101 in Subjects With Interstitial Cystitis/Bladder Pain SyndromeA Phase 2a, Randomized, Double-Blind, Placebo-Controlled Multi-Center Single Dose Study to Evaluate the Safety and Effectiveness of URG101 Compared With the Individual Components Lidocaine and Heparin in Subjects With Interstitial Cystitis/Bladder Pain SyndromeInterstitial Cystitis;Bladder Pain SyndromeDrug: URG101;Drug: Placebo;Drug: Lidocaine;Drug: HeparinUrigenNot recruiting18 YearsN/AAll92Phase 2United States
22NCT01393223July 21, 201512 November 2018Evaluation of Intravesical LP08 in Patients With Interstitial Cystitis/Painful Bladder SyndromeA Single-Center, Double-Blind, Randomized, Dose-Ranging, Placebo Controlled Trial Comparing the Safety, Tolerability and Efficacy of LP-08 With Placebo in Subjects With Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS)Interstitial CystitisDrug: LP-08 80mg;Drug: Normal saline;Drug: LP-08 20mgLipella Pharmaceuticals, Inc.William Beaumont HospitalsNot recruiting18 Years70 YearsAll21Phase 2United States
23NCT02395042April 30, 201529 January 2018A Safety and Efficacy Study of LiRIS® in Females With Interstitial Cystitis With Hunner's LesionsA Multicenter, Randomized, Double-blind, Placebo-controlled Study, Evaluating Safety and Efficacy of LiRIS® 400 mg in Females With Interstitial Cystitis With Hunner's LesionsCystitis, Interstitial;UlcerDrug: LiRIS®;Drug: LiRIS PlaceboAllerganNot recruiting18 YearsN/AFemale62Phase 2United States;Canada
24NCT03076762March 201516 December 2017Comparative Study Suburothelial and Trigonal Botulinum Toxin A Injection in Treatment of Interstitial CystitisComparative Study of the Efficacy and Safety Between Suburothelial and Trigonal Intravesical Botulinum Toxin A Injection in Treatment of Interstitial Cystitis Refractory to Conventional Treatment - A Prospective, Randomized, Clinical TrialBladder Pain SyndromeDrug: intravesical onabotulinumtoxinA injectionBuddhist Tzu Chi General HospitalRecruiting18 YearsN/AAll60Phase 2Taiwan
25NCT02517996February 201515 July 2019Use of Preemptive Pudendal Nerve Block Prior to Hydrodistention for the Treatment of Interstitial Cystitis/Painful Bladder Syndrome (IC/PBS)Use of Preemptive Pudendal Nerve Block Prior to Hydrodistension for the Treatment of Interstitial Cystitis/Painful Bladder Syndrome (IC/PBS): a Prospective, Double-blinded, Randomized Control TrialInterstitial Cystitis;Painful Bladder SyndromeDrug: Lidocaine;Drug: PlaceboJohns Hopkins UniversityNot recruiting18 YearsN/AFemale18N/AUnited States
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
26NCT02297100December 201411 June 2018Intravesicular Onabotulinumtoxin A in Interstitial CystitisThe Impact of Injection Location on the Efficacy of Intravesicular Onabotulinumtoxin A in Interstitial Cystitis--Phase 4Interstitial CystitisDrug: Onabotulinumtoxin A;Procedure: injections upper aspect of trigone of urinary bladder;Procedure: injections on posterior bladder wall excluding the trigoneWake Forest University Health SciencesAllerganNot recruiting18 Years80 YearsFemale27Phase 4United States
27NCT02247557September 201416 December 2017Intravesical Instillation of Liposome Encapsulated Botulinum Toxin A (Lipotoxin) in Treatment of Interstitial CystitisIntravesical Instillation of Liposome Encapsulated Botulinum Toxin A (Lipotoxin) in Treatment of Interstitial Cystitis — a Randomized, Double-blind, Placebo-controlled, Prospective StudyInterstitial CystitisDrug: Liposome encapsulated BoNT-A;Drug: BOTOX 200U in normal saline;Drug: Normal salineBuddhist Tzu Chi General HospitalNot recruiting20 Years80 YearsAll90Phase 2Taiwan
28JPRN-UMIN0000091972014/07/012 April 2019Safety and efficacy of tramadol in the treatment of refractory pain of interstitial cystitis: a double-blind, placebo-controlled, randomized prospective studyinterstitial cystitisoral administration of Tramadol after randomization
oral administration of placebo after randomization
Departmen of Urology, The University of Tokyo HospitalNot Recruiting20years-old80years-oldMale and Female90Not applicableJapan
29NCT01990898November 201316 December 2017Cyclosporine in Interstitial Cystitis: Efficacy, Safety and Mechanism of ActionCyclosporine in Interstitial Cystitis: Efficacy, Safety and Mechanism of ActionInterstitial CystitisDrug: CyclosporineThe Cleveland ClinicNot recruiting18 Years80 YearsAll26Phase 2United States
30NCT01879683July 201319 October 2017A Safety, Tolerability and Preliminary Efficacy Study of LiRIS® 400 mg in Women With Interstitial Cystitis (IC) and Hunner's LesionsA Phase 1b, Multicenter, Open Label Study Evaluating Safety, Tolerability and Preliminary Efficacy of LiRIS® 400 mg in Women With Ulcerative Interstitial CystitisChronic Interstitial CystitisDrug: LiRIS® 400 mgAllerganTARIS Biomedical, Inc.Not recruiting18 YearsN/AFemale10Phase 1United States
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
31NCT01882543June 201316 December 2017Efficacy and Safety of AQX-1125 in IC/BPSA Phase 2 Study to Evaluate the Efficacy and Safety of AQX-1125 in Subjects With Interstitial Cystitis/Bladder Pain Syndrome Mediated by the Src Homology-2-domain-containing Inositol 5' Phosphatase [SHIP1] PathwayInterstitial Cystitis;Bladder Pain SyndromeDrug: AQX-1125;Drug: PlaceboAquinox Pharmaceuticals (Canada) Inc.Not recruiting18 Years75 YearsFemale69Phase 2United States;Canada
32NCT01813565March 20, 201315 July 2019The Efficacy of Additional Intravesical Instillation of Hyaluronic Acid/Chondroitin Sulfate to Transurethral Resection of Bladder Ulcer in Patients With Interstitial Cystitis/Bladder Pain Syndrome.The Efficacy of Additional Intravesical Instillation of Hyaluronic Acid/Chondroitin Sulfate to Transurethral Resection of Bladder Ulcer in Patients With Interstitial Cystitis/Bladder Pain Syndrome.Interstitial CystitisDrug: Hyaluronic acid/chondroitin sulfateAsan Medical CenterNot recruiting20 YearsN/AAll15N/AKorea, Republic of
33NCT01824303March 201319 October 2017Safety, Tolerability and Efficacy Study of LiRIS® 400 mg in Women With Interstitial CystitisA Phase 2 Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study Evaluating Safety, Tolerability and Efficacy of LiRIS® 400 mg in Women With Interstitial Cystitis Followed by an Open Label ExtensionInterstitial CystitisDrug: LiRIS 400 mg;Other: LiRIS PlaceboAllerganTARIS Biomedical, Inc.Not recruiting18 YearsN/AFemale31Phase 2United States;Canada
34JPRN-JMA-IIA0011327/02/20132 April 2019Multi-center clinical study on the effect of glycine for disorders of urine storageMulti-center clinical study on the effect of glycine for disorders of urine storageOveractive bladder, chronic prostatitis, interstitial cystitis, and nocturiaIntervention type:DRUG. Intervention1:glycine, Dose form:POWDER, Route of administration:ORAL, intended dose regimen:Oral administration of Glycine 3g, twice a day, for 8 weeks . Control intervention1:glucose, Dose form:POWDER, Route of administration:ORAL, Intended dose regimen:Oral administration of Glucose 3g, twice a day, for 8 weeks .Kimio Sugaya (Kitakami Central Hospital, and Southern Knights' Laboratory LLP)Okinawa Kyodo Hospital, Kawahara Nephro-urology Clinic, Yamada Urologic Clinic, Akita Urologic Clinic, Kobe Medical Center, Kitanodai Clinic, Yokohama Motimachi Womens' Clinic LUNA, Nanbu Tokushukai Hospital, Okinawa Kokubu HospitalNot Recruiting>=20 YEARSNo LimitBOTH160NOT APPLICABLEJapan
35NCT01048177December 201219 February 2015A Trial of Intravesical Therapy for Interstitial Cystitis in Patients With Generalized VulvodyniaA Trial of Intravesical Therapy for Interstitial Cystitis in Patients With Generalized VulvodyniaVulvodyniaDrug: Bladder instillation with heparin/ lidocaineScripps HealthNot recruiting18 Years80 YearsFemale0Phase 2United States
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
36NCT01969773December 201216 December 2017Intravesical Botulinum Toxin A Injections in Treatment of Interstitial Cystitis Refractory to Conventional TreatmentIntravesical Botulinum Toxin A Injection in Treatment of Interstitial Cystitis Refractory to Conventional Treatment - A Prospective, Multicenter, Randomized, Double-blind, Placebo-controlled Clinical TrialInterstitial CystitisDrug: Botulinum toxin A;Drug: Normal saline instillationBuddhist Tzu Chi General HospitalNot recruiting20 Years85 YearsAll60Phase 2Taiwan
37NCT01678911August 201219 October 2017Efficacy of Gralise® for Chronic Pelvic PainEfficacy of Gralise® for Chronic Pelvic PainIrritable Bowel Syndrome;Ulcerative Colitis;Interstitial Cystitis;Prostatitis;Pelvic PainDrug: GraliseShirley Ryan AbilityLabNot recruiting18 YearsN/AAll11Phase 4United States
38JPRN-UMIN0000084842012/07/232 April 2019aInterstitial cystitis/ Hypersensitive bladder syndromeAdministration of mirabegron 50mg per day for four weeks.Department of Urology, Graduate school of medicine, University of TokyoNot Recruiting20years-oldNot applicableMale and Female20Not selectedJapan
39NCT01731470July 201219 October 2017Intravesical Liposomes for Interstitial Cystitis/Painful Bladder Syndrome (IC/PBS)Intravesical Liposomes for Interstitial Cystitis/Painful Bladder Syndrome (IC/PBS)Interstitial Cystitis;Pelvic PainBiological: LiposomesKenneth Peters, MDWilliam Beaumont HospitalsNot recruiting18 YearsN/AAll14N/AUnited States
40NCT01613586May 31, 201228 January 2019A Randomized Study Comparing Placebo and ASP3652 in the Treatment of Women With Bladder Pain Syndrome / Interstitial Cystitis (BPS/IC)A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel Group, Adaptive, Combined Proof of Concept and Dose-Finding Study to Investigate Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of ASP3652 in the Treatment of Female Patients With Bladder Pain Syndrome / Interstitial CystitisCystitis, Interstitial;Urinary Bladder Disease;Pain;Urologic DiseasesDrug: ASP3652;Drug: PlaceboAstellas Pharma Europe B.V.Not recruiting18 YearsN/AFemale287Phase 2Belgium;Czechia;Denmark;Germany;Latvia;Lithuania;Netherlands;Poland;Portugal;Romania;Russian Federation;Spain;Czech Republic
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
41EUCTR2011-004555-39-BE07/05/201221 August 2017A Randomized Study comparing Placebo and ASP3652 in the treatment of women with Bladder Pain Syndrome / Interstitial CystitisA Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel group, Adaptive, combined Proof of Concept and Dose-Finding study to investigate Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of ASP3652 in the treatment of female subjects with Bladder Pain Syndrome / Interstitial Cystitis - AMARANTHBladder Pain Syndrome / Interstitial Cystitis
MedDRA version: 14.1 Level: LLT Classification code 10071166 Term: Bladder pain syndrome System Organ Class: 10038359 - Renal and urinary disorders
MedDRA version: 14.1 Level: LLT Classification code 10008928 Term: Chronic interstitial cystitis NOS System Organ Class: 10038359 - Renal and urinary disorders
MedDRA version: 14.1 Level: LLT Classification code 10008927 Term: Chronic interstitial cystitis System Organ Class: 10038359 - Renal and urinary disorders
MedDRA version: 14.1 Level: PT Classification code 10011796 Term: Cystitis interstitial System Organ Class: 10038359 - Renal and urinary disorders ;Therapeutic area: Diseases [C] - Female diseases of the urinary and reproductive systems and pregancy complications [C13]
Product Name: ASP3652
Product Code: ASP3652
Pharmaceutical Form: Film-coated tablet
Current Sponsor code: ASP3652
Other descriptive name: ASP3652
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 25-
Pharmaceutical form of the placebo: Film-coated tablet
Route of administration of the placebo: Oral use
Product Name: ASP3652
Product Code: ASP3652
Pharmaceutical Form: Film-coated tablet
Current Sponsor code: ASP3652
Other descriptive name: ASP3652
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 100-
Pharmaceutical form of the placebo: Film-coated tablet
Route of administration of the placebo: Oral use
Astellas Pharma Europe B.V.Not RecruitingFemale: yes
Male: no
300Phase 2Portugal;Spain;Lithuania;Russian Federation;Italy;France;Czech Republic;Belgium;Poland;Romania;Denmark;Germany;Latvia;Netherlands
42NCT02000401May 201219 February 2015Intranasal Ketorolac Tromethamine (Sprix) for Acute Pain of Interstitial Cystitis Flare of PainTo Evaluate the Efficacy, Tolerability, and Safety of Intranasal Ketorolac Tromethamine (Sprix) as an Option for Acute (up to 5 Days) Pain Management Adult Interstitial Cystitis Patients Experiencing a Flare of PainInterstitial CystitisDrug: Ketorolac TromethamineCitrus Valley Medical Research, Inc.Not recruiting18 Years64 YearsFemale15Phase 4United States
43NCT01569438April 13, 201215 July 2019The Safety and Efficacy of Gefapixant (AF-219/MK-7264) in Female Subjects With Interstitial Cystitis /Bladder Pain SyndromeBladder Pain SyndromeDrug: Gefapixant;Drug: Sugar PillAfferent Pharmaceuticals, Inc.Not recruiting18 Years80 YearsFemale74Phase 2United States
44NCT01559961March 201219 February 2015Safety Study of Single Intravesical Doses of TTI-1612 in Women With Interstitial Cystitis/Bladder Pain SyndromeA Phase I Dose Escalation Study of the Safety and Pharmacokinetics of Single Intravesical Doses of TTI-1612 in Women With Interstitial Cystitis/Bladder Pain SyndromeInterstitial CystitisDrug: TTI-1612Trillium Therapeutics Inc.Not recruiting18 Years65 YearsFemale28Phase 1Canada
45JPRN-UMIN0000063872011/11/012 April 2019Clinical study on the intravesical instillation of heparin, lidocain and bicarbonate for the patients with interstitial cystitisinterstitital cystitisIntravesical instillation of heparin, lidocain and bicarbonateUniversity of TokushimaNot RecruitingNot applicableNot applicableMale and Female30Phase 2Japan
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
46NCT01475253November 201119 October 2017Double-Blind Placebo Controlled Study of Safety,Tolerability, and Efficacy of LiRIS® in Women With Interstitial CystitisA Phase 2a Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study Evaluating Safety, Tolerability and Efficacy of LiRIS® in Women With Interstitial Cystitis Followed by an Open Label ExtensionInterstitial CystitisDrug: Lidocaine Releasing Intravesical System - LiRIS®;Other: LiRIS Placebo;Procedure: Sham Cystoscopy ProcedureAllerganTARIS Biomedical, Inc.Not recruiting18 YearsN/AFemale104Phase 2United States;Canada
47NCT01378754June 201119 February 2015Evaluate The Effectiveness Of Fospropofol (Lusedra®) For Induction Of AnesthesiaA DOSE RANGING STUDY TO EVALUATE THE EFFECTIVENESS OF FOSPROPOFOL (LUSEDRA®) FOR INDUCTION OF ANESTHESIA FOR OUTPATIENT UROLOGIC HYDRODILATION THERAPYInterstitial CystitisDrug: Fospropofol (Lusedra®) 6.5;Drug: Fospropofol (Lusedra®) 10;Drug: Fospropofol (Lusedra®) 12Grace Shih, MDNot recruiting18 Years65 YearsBoth0N/AUnited States
48NCT01295814March 201119 October 2017Efficacy Study of Adalimumab to Treat Interstitial CystitisAn Investigator Initiated, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy of Humira® (Adalimumab) For The Treatment of Interstitial Cystitis(IC)Interstitial CystitisDrug: Adalimumab;Other: inactive drugICStudy, LLCAbbottNot recruiting18 Years65 YearsAll43Phase 3United States
49EUCTR2010-021556-25-IT24/02/201123 December 2013Phase III, randomized, open-label, multicenter evaluation of efficacy and tolerability `of Ialuril (sodium hyaluronate-chondroitin sulfate) vs. dimethyl sulfoxide (DMSO) in women with interstitial cystitis / painful bladder syndrome (IC / BPS) Ascolta Trascrizione fonetica Dizionario - Visualizza dizionario dettagliato - IBSA 01-2010Phase III, randomized, open-label, multicenter evaluation of efficacy and tolerability `of Ialuril (sodium hyaluronate-chondroitin sulfate) vs. dimethyl sulfoxide (DMSO) in women with interstitial cystitis / painful bladder syndrome (IC / BPS) Ascolta Trascrizione fonetica Dizionario - Visualizza dizionario dettagliato - IBSA 01-2010Interstitial Cystitis
MedDRA version: 9.1 Level: HLGT Classification code 10018188
Trade Name: RIMSO 50
Pharmaceutical Form: Bladder irrigation
INN or Proposed INN: Dimethyl sulfoxide
Concentration unit: g gram(s)
Concentration type: equal
Concentration number: .54-
IBSANot RecruitingFemale: yes
Male: no
Phase 3Italy
50NCT01197261September 20105 November 2018OXN PR vs Placebo in Opioid-naive Subjects Suffering From Severe Pain Due to Bladder Pain Syndrome (BPS)An Exploratory, Randomised, Double-blind, Placebo-controlled, Parallel Group, Pilot Study to Assess the Analgesic Efficacy of Oxycodone/Naloxone Prolonged Release Tablets (OXN PR) Compared to Placebo in Opioid-naive Subjects Suffering From Severe Pain Due to Bladder Pain Syndrome.Interstitial Cystitis;Painful Bladder Syndrome;PainDrug: Oxycodone naloxone prolonged release tablets;Drug: Placebo tabletsMundipharma Research GmbH & Co KGNot recruiting18 YearsN/AFemale120Phase 2Czechia;Germany;Hungary;Poland;United Kingdom;Czech Republic
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
51NCT01083979August 201019 October 2017Intravesical Liposomes for Ulcerative CystitisIntravesical Liposomes for Ulcerative CystitisInterstitial CystitisDrug: LiposomesKenneth Peters, MDNot recruiting20 YearsN/AAll1N/AUnited States
52NCT01150565July 201019 February 2015Safety Study of LiRIS in Interstitial Cystitis (IC) PatientsPhase 1B Pilot Safety Study of LiRIS-TM, A Novel Bladder Drug Delivery Platform in Patients With Interstitial CystitisInterstitial CystitisDrug: LiRIS low dose and LiRIS high doseAllerganTARIS Biomedical, Inc.Not recruiting18 YearsN/AFemale18Phase 1Canada
53NCT00919802June 201016 December 2017Intranasal Oxytocin for the Treatment of Pain Associated With Interstitial CystitisIntranasal Oxytocin for the Treatment of Pain Associated With Interstitial CystitisInterstitial CystitisDrug: Oxytocin;Other: Saline as a nasal sprayUniversity of Alabama at BirminghamNot recruiting19 Years65 YearsAll25Phase 4United States
54EUCTR2009-014597-17-SE03/05/20103 December 2012A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE RANGING STUDY EVALUATING THE EFFICACY AND SAFETY OF TANEZUMAB FOR THE TREATMENT OF MODERATE TO SEVERE PAIN ASSOCIATED WITH INTERSTITIAL CYSTITIS/ PAINFUL BLADDER SYNDROME (IC/PBS)A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE RANGING STUDY EVALUATING THE EFFICACY AND SAFETY OF TANEZUMAB FOR THE TREATMENT OF MODERATE TO SEVERE PAIN ASSOCIATED WITH INTERSTITIAL CYSTITIS/ PAINFUL BLADDER SYNDROME (IC/PBS)Chronic pain including the pain of interstitial cystitis/painful bladder syndrome.
MedDRA version: 12.0 Level: LLT Classification code 10008927 Term: Chronic interstitial cystitis
Product Name: Tanezumab
Product Code: PF-04383119
Pharmaceutical Form: Solution for injection
INN or Proposed INN: Tanezumab
CAS Number: 880266-57-9
Current Sponsor code: PF-04383119
Other descriptive name: RN624, RI624
Concentration unit: mg/ml milligram(s)/millilitre
Concentration type: equal
Concentration number: 2.5-
Pharmaceutical form of the placebo: Solution for injection
Route of administration of the placebo: Subcutaneous use
Product Name: Tanezumab
Product Code: PF-04383119
Pharmaceutical Form: Solution for injection
INN or Proposed INN: Tanezumab
CAS Number: 880266-57-9
Current Sponsor code: PF-04383119
Other descriptive name: RN624, RI624
Concentration unit: mg/ml milligram(s)/millilitre
Concentration type: equal
Concentration number: 10-
Pharmaceutical form of the placebo: Solution for injection
Route of administration of the placebo: Subcutaneous use
Product Name: Tanezumab
Product Code: PF-04383119
Pharmaceutical Form: Solution for injection
INN or Proposed INN: Tanezumab
CAS Number: 880266-57-9
Current Sponsor code: PF-04383119
Other descriptive name: RN624, RI624
Concentration unit: mg/ml milligram(s)/millilitre
Concentration type: equal
Concentration number: 20-
Pharmaceutical form of the placebo: Solution for injection
Route of administration of the placebo: Subcutaneous use
Pfizer Inc., 235 East 42nd Street, New York, NY 10017Not RecruitingFemale: yes
Male: yes
300Phase 2BFinland;Spain;Belgium;Germany;Sweden
55NCT01195116May 201019 October 2017Usefulness of Dexmedetomidine on Post-operative Pain Management in Patients With Interstitial CystitisUsefulness of Dexmedetomidine on Post-operative Pain Management in Patients With Interstitial CystitisInterstitial CystitisDrug: Dexmedetomidine;Drug: Normal SalineUniversity of RochesterNot recruiting18 YearsN/AAll41Phase 4United States
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
56NCT01069263February 201019 February 2015Comparative Study Between Hyperbaric Therapy and Intravesical Dimethyl Sulfoxide Instillation for Interstitial CystitisComparison Between Hyperbaric Oxygen Therapy (HBOT) and Intravesical Dimethyl Sulfoxide (DMSO) Instillation for the Treatment of Interstitial Cystitis - a Prospective, Randomized Cross-over TrialInterstitial CystitisOther: Hyperbaric Oxygen Therapy;Drug: DMSOAssaf-Harofeh Medical CenterRecruiting18 Years85 YearsBoth60N/AIsrael
57NCT00999518January 201019 February 2015A Study To Investigate Tanezumab In Patients With Interstitial Cystitis/ Painful Bladder SyndromeA Phase 2B, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study Evaluating The Efficacy And Safety Of Tanezumab For The Treatment Of Moderate To Severe Pain Associated With Interstitial Cystitis/ Painful Bladder Syndrome (IC/PBS)Cystitis, InterstitialBiological: Tanezumab;Other: PlaceboPfizerNot recruiting18 YearsN/ABoth222Phase 2United States;Belgium;Canada;Finland;Hong Kong;Japan;Korea, Republic of;Poland;Romania;Russian Federation;Slovakia;Spain;Sweden;Taiwan;India;South Africa;Germany
58NCT01030640December 200919 February 2015Study To Assess Changes In The Number Of Nerves In The Skin At The Site Where Where Tanezumab Is InjectedA Phase 1, Randomized, Double- Blind (Sponsor-Open), Placebo-Controlled Study To Examine The Density Of Intraepidermal Nerve Fibers After A Single Subcutaneous Administration Of Tanezumab In Healthy VolunteersOsteoarthritis Pain;Chronic Low Back Pain;Pain Due to Interstitial CystitisOther: placebo;Biological: tanezumabPfizerNot recruiting18 Years55 YearsBoth28Phase 1United States
59NCT01074567December 200919 February 2015DMSO Efficacy in IC/PBS Patients During and After TreatmentEfficacy of DMSO Cocktail Treatment in Interstitial Cystitis Patients During and After TreatmentCystitis, InterstitialDrug: DMSO cocktailAssaf-Harofeh Medical CenterRecruiting18 YearsN/AFemale50N/AIsrael
60NCT01616992September 200919 February 2015Interstitial Cystitis: Elucidation of the Psychophysiologic and Autonomic Characteristics (ICEPAC) StudyInterstitial Cystitis: Elucidation of the Psychophysiologic and AutonomicInterstitial Cystitis/Painful Bladder Syndrome;Myofascial Pelvic PainDrug: BupivacaineCase Western Reserve UniversityNot recruiting18 Years80 YearsFemale200N/AUnited States
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
61NCT00919113July 200919 October 2017Efficacy and Safety Study of Uracyst to Treat Interstitial Cystitis/Painful Bladder SyndromeA Multi-Center, Randomized, Double-Blind, Parallel Group Evaluation of the Effectiveness and Safety of Uracyst® Compared to Inactive Control in Subjects With Interstitial Cystitis/Painful Bladder SyndromeInterstitial Cystitis;Painful Bladder SyndromeDrug: 2% sodium chondroitin sulfate;Drug: PlaceboWatson PharmaceuticalsNot recruiting18 YearsN/AFemale98Phase 2United States
62ChiCTR-TRC-130039382009-06-0118 April 2017Efficacy of daily low-dose sildenafil for treating interstitial cystitis: results of randomized, double-blind, placebo-controlled trialEfficacy of daily low-dose sildenafil for treating interstitial cystitis: results of randomized, double-blind, placebo-controlled trialinterstitial cystitisgroup A:oral sildenafil;group B:oral placebo ;The First Af?liated Hospital of Wenzhou Medical CollegeNot Recruiting3555Bothgroup A:24;group B:24;Post-marketChina
63NCT01294878March 200919 February 2015Omalizumab in Interstitial Cystitis/Bladder Pain SyndromeExplorative Study on the Use of Omalizumab in Patients Suffering From Interstitial Cystitis/Painful Bladder SyndromeInterstitial Cystitis;Painful Bladder SyndromeDrug: omalizumabIRCCS Policlinico S. MatteoNot recruiting18 YearsN/AFemale3Phase 3Italy
64NCT00823030January 200926 October 2015Effect of Intravesical Lidocaine on Urodynamic and Symptomatic Parameters of Interstitial CystitisEffect of Intravesical Lidocaine on Urodynamic and Symptomatic Parameters of Interstitial CystitisInterstitial CystitisProcedure: Urodynamic study;Drug: Lidocaine;Other: Normal SalineNorth Shore Long Island Jewish Health SystemNot recruiting18 Years80 YearsBoth0N/AUnited States
65EUCTR2009-018118-21-DE31 March 2014not applicableAn exploratory, randomised, double-blind, placebo-controlled, parallel group, pilot study to assess the analgesic efficacy of oxycodone/naloxone prolonged release tablets (OXN PR) compared to placebo in opioid-naïve Subjects suffering from severe pain due to Bladder Pain Syndrome. - not applicableBladder Pain Syndrome (BPS), formerly addressed as IC/PBS (interstitial cystitis /Painful Bladder Syndrome)
MedDRA version: 14.1 Level: LLT Classification code 10008927 Term: Chronic interstitial cystitis System Organ Class: 100000004857 ;Therapeutic area: Diseases [C] - Female diseases of the urinary and reproductive systems and pregancy complications [C13]
Trade Name: Targinact 5mg/2.5 mg prolonged-release tablets
Product Name: oxycodone/naloxone prolonged release tablets 5/2.5 mg
Product Code: OXN 5/2.5 mg PR
Pharmaceutical Form: Prolonged-release tablet
CAS Number: 124-90-3
Other descriptive name: OXYCODONE HYDROCHLORIDE
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 5.0-
CAS Number: 357-08-4
Other descriptive name: NALOXONE HYDROCHLORIDE
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 2.5-
Pharmaceutical form of the placebo: Prolonged-release tablet
Route of administration of the placebo: Oral use
Trade Name: Targinact 10 mg/5 mg prolonged-release tablets
Product Name: oxycodone/naloxone prolonged release tablets 10/5 mg
Product Code: OXN 10/5 mg PR
Pharmaceutical Form: Prolonged-release tablet
CAS Number: 124-90-3
Other descriptive name: OXYCODONE HYDROCHLORIDE
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 10.0-
CAS Number: 357-08-4
Other descriptive name: NALOXONE HYDROCHLORIDE
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 5.0-
Pharmaceutical form of the placebo: Prolonged-release tablet
Route of administration of the placebo: Oral use
Trade Name: Targinact 20mg/10 mg prolonged-release tablets
Product Name: oxycodone/naloxone prolonged release tablets 20/10 mg
Product Code: OXN 20/10 mg PR
Pharmaceutical Form: Prolonged-release tablet
CAS Number: 124-90-3
Other descriptive name: OXYCODONE HYDROCHLORIDE
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 20.0-
CAS Number: 357-08-4
Other descriptive name: NALOXONE HYDROCHLORIDE
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 10.0-
Pharmaceutical form of the placebo: Prolonged-release tablet
Route of administration of the placebo: Oral use
Trade Name: Targinact 5mg/2.5 mg prolonged-release tablets
Mundipharma Research GmbH & Co. KGNot RecruitingFemale: yes
Male: no
70Czech Republic;Hungary;Germany;United Kingdom
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
66NCT00739739August 200819 February 2015An Effectiveness And Safety Study Of PD 0299685 For The Treatment Of Symptoms Associated With Interstitial CystitisA Phase 2, 12 Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Proof Of Concept Study Evaluating The Efficacy And Safety Of PD 0299685 For The Treatment Of Symptoms Associated With Interstitial Cystitis/Painful Bladder Syndrome.Interstitial Cystitis;Painful Bladder SyndromeDrug: PD 0299685 at 15mg BID;Drug: PD 0299685 at 30mg BID;Drug: placebo for PD 0299685PfizerNot recruiting18 YearsN/ABoth161Phase 2United States;Canada;Denmark;Finland;France;Germany
67JPRN-UMIN0000012532008/07/012 April 2019A randomized trial to asses the effects of hydrogen-rich dissolution water in patients with interstitial cystitisInterstitial cystitisThe patients will be intervened with hydrogen dissolution water group (hydrogen group) 200ml every three times in a day in 2 months (56days).
After that, the patients in hydrogen dissolution water group will be transferred to the additional intervention term after the end of intervention.
And after that, the patients will be randomized to withdrawal terms for more 1 month with hydrogen dissolution water or with placebo water.

The patients will be intervened with normal water (placebo group) 200ml every three times in a day in 2 months (56days)
After that, the patients in placebo water group will be given hydrogen water for more 1 month.
Koushinkai HospitalNot Recruiting20years-old80years-oldMale and Female30Phase 2,3Japan
68EUCTR2008-001501-42-FI15/05/200819 March 2012Tacrolimus in the treatment of Painful Bladder Syndrome / Interstitial CystitisTacrolimus in the treatment of Painful Bladder Syndrome / Interstitial CystitisPainful bladder syndrome / interstitial cystitis (PBS/IC)
MedDRA version: 1 Level: LLT Classification code 10005063 Term:
Trade Name: Prograf
Pharmaceutical Form:
INN or Proposed INN: TACROLIMUS
CAS Number: 104987113
Jukka SairanenAuthorisedFemale: yes
Male: yes
Finland
69NCT00601484March 200819 February 2015An Effectiveness and Safety Study of PF-04383119 for the Treatment of Pain in Interstitial CystitisA Phase 2, 16 Week, Multicenter, Randomized, Double Blind Placebo Controlled, Parallel Group Proof Of Concept Study Evaluating The Efficacy And Safety Of PF-04383119 For The Treatment Of Pain Associated With Interstitial CystitisCystitis, InterstitialDrug: PF-04383119;Drug: PlaceboPfizerNot recruiting18 YearsN/ABoth65Phase 2United States
70EUCTR2007-005164-27-NL22/02/200819 March 2012Botulinum toxin A intravesical injections in the treatment of Bladder Pain Syndrome/ Interstitial CystitisBotulinum toxin A intravesical injections in the treatment of Bladder Pain Syndrome/ Interstitial CystitisInterstitial Cystitis (IC) is a syndrome characterized by bladder pain associated with urgency, frequency, nocturia, dysuria and sterile urine. The patho-physiology remains largely unclear. No universally, effective, treatment exists. Botulinum toxin-A (BTX-A) inhibits the release of acetylcholine at the presynaptic cholinergic junction resulting in temporally muscle relaxation and bladder desensitisation. We explore the effects of intravesical injections with BTX-A in the treatment of IC.Trade Name: Botox
Pharmaceutical Form: Concentrate for solution for injection
research office urology VUmcAuthorisedFemale: yes
Male: yes
12Netherlands
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
71EUCTR2008-002421-37-DE1 May 2012A PHASE 2, 12 WEEK, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED, PARALLEL GROUP, PROOF OF CONCEPT STUDY EVALUATING THE EFFICACY AND SAFETY OF PD 0299685 FOR THE TREATMENT OF SYMPTOMS ASSOCIATED WITH INTERSTITIAL CYSTITIS/PAINFUL BLADDER SYNDROME.A PHASE 2, 12 WEEK, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED, PARALLEL GROUP, PROOF OF CONCEPT STUDY EVALUATING THE EFFICACY AND SAFETY OF PD 0299685 FOR THE TREATMENT OF SYMPTOMS ASSOCIATED WITH INTERSTITIAL CYSTITIS/PAINFUL BLADDER SYNDROME.INTERSTITIAL CYSTITIS/PAINFUL BLADDER SYNDROME.
MedDRA version: 9.1 Level: LLT Classification code 10008927 Term: Chronic interstitial cystitis
Product Name: PD 0299685
Pharmaceutical Form: Capsule, hard
CAS Number: 313651-33-1
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 5-
Pharmaceutical form of the placebo: Capsule, hard
Route of administration of the placebo: Oral use
Product Name: PD 0299685
Pharmaceutical Form: Capsule, hard
CAS Number: 313651-33-1
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 10-
Pharmaceutical form of the placebo: Capsule, hard
Route of administration of the placebo: Oral use
Pfizer Ltd., Ramsgate Road, Sandwich, Kent, CT13 9NJ, UKNot RecruitingFemale: yes
Male: yes
147Phase 2Finland;Germany;Denmark;France
72NCT00451867March 200719 February 2015A Randomized Multicenter Double-Blind CT to Evaluate the Efficacy and Safety of Mycophenolate Mofetil . . .A Randomized Multicenter Double-Blind Clinical Trial to Evaluate the Efficacy and Safety of Mycophenolate Mofetil (CellCept) for the Treatment of Refractory Interstitial Cystitis (IC)Interstitial Cystitis;Painful Bladder SyndromeDrug: Mycophenolate Mofetil;Drug: Mycofenolate Mofetil (MMF);Drug: PlaceboNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Not recruiting18 YearsN/ABoth210Phase 3United States;Canada
73NCT00380783October 200619 February 2015Safety and Efficacy of AGN 203818 for Pain Associated With Painful Bladder Syndrome/Interstitial CystitisCystitis, InterstitialDrug: AGN 203818AllerganNot recruiting18 YearsN/AFemale2Phase 2United States
74NCT00275379August 200619 February 2015Study Evaluating Orally Administered ERB-041 in Subjects With Active Interstitial CystitisA Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, Exploratory Study of Orally Administered ERB-041 in Subjects With Active Interstitial CystitisCystitis, InterstitialDrug: ERB-041Wyeth is now a wholly owned subsidiary of PfizerNot recruiting18 YearsN/AFemale60N/AUnited States;Austria;Germany
75NCT00317070April 200619 February 2015Trial Comparing Intravesical Cocktail With Intravesical Dimethyl Sulfoxide (DMSO) in Painful Bladder Syndrome/Interstitial Cystitis (PBS/IC)A Randomized Controlled Trial to Evaluate the Efficacy and Tolerability of Intravesical Cocktail and Comparison With Intravesical Dimethyl Sulfoxide (DMSO) for the Treatment of Painful Bladder Syndrome Including Interstitial Cystitis (PBS/IC)Interstitial Cystitis;Bladder DiseasesDrug: dimethyl sulfoxide;Drug: IC CocktailCapital District Health Authority, CanadaNot recruiting18 YearsN/ABoth10Phase 2Canada
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
76EUCTR2005-003367-23-DE13/02/200619 March 2012A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of YM672 in the Treatment of Painful Bladder Syndrome/Interstitial Cystitis - Not availableA Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of YM672 in the Treatment of Painful Bladder Syndrome/Interstitial Cystitis - Not availableInterstitial Cystitis / Painful Bladder Syndrome
MedDRA version: 8.0 Level: LLT Classification code 10008928
Product Name: YM672 (IPD®)
Product Code: YM672
Pharmaceutical Form: Film-coated tablet
INN or Proposed INN: Suplatast tosilate
Current Sponsor code: YM672
Other descriptive name: IPD® (Japanese tradename)
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 200-
Pharmaceutical form of the placebo: Film-coated tablet
Route of administration of the placebo: Oral use
Astellas Pharma Europe B.V.Not RecruitingFemale: yes
Male: yes
150Phase 2Germany;Sweden
77NCT00256542January 200619 February 2015Study of U101 for Bladder Pain and/or UrgencyA Phase II Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Intravesical Alkalinized Lidocaine-Heparin for the Symptoms of Pelvic Pain and/or Urgency of Bladder OriginPelvic Pain;Interstitial Cystitis;Bladder DiseasesDrug: Alkalinized Lidocaine-HeparinUrigenNot recruiting18 YearsN/ABoth90Phase 2United States
78EUCTR2005-000890-23-SE13/10/200519 March 2012NO as an objective marker for inflammation in patients with interstitial cystitis treated with cyclosporine.NO as an objective marker for inflammation in patients with interstitial cystitis treated with cyclosporine.Interstitiell cystitTrade Name: Sandimmun Neoral
Product Name: Sandimmun Neoral
Pharmaceutical Form: Capsule*
INN or Proposed INN: Ciklosporin
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 10, 25, 50, 100-
Ingrid EhrénNot RecruitingFemale: yes
Male: yes
15Sweden
79NCT00295854May 200519 October 2017Phase II Study Efficacy and Safety of Two Dosing Regimens of MN-001 in Patients With Interstitial CystitisA Phase II, Randomized, Double-blind, Placebo-controlled, Multi-center Study to Evaluate the Efficacy and Safety of Two Dosing Regimens of MN-001 in Patients With Interstitial CystitisInterstitial CystitisDrug: MN-001 BID;Drug: MN-001;Drug: PlaceboMediciNovaNot recruiting18 YearsN/AAll296Phase 2United States
80NCT00124306February 200519 February 2015Efficacy of Amitriptyline for Painful Bladder Syndrome (PBS)A Randomized Multicenter Clinical Trial to Evaluate the Efficacy of Amitriptyline for the Treatment of Painful Bladder Syndrome (PBS) in Newly Diagnosed PatientsBladder Diseases;Interstitial CystitisDrug: Amitriptyline;Other: PlaceboNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)University of PennsylvaniaNot recruiting18 YearsN/ABoth271Phase 3United States;Canada
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
81NCT00194610May 200419 October 2017Botox as a Treatment for Interstitial Cystitis in WomenBotox (Botulinum Toxin A) as a Treatment for Interstitial Cystitis in Women: A Randomized Placebo Controlled TrialPainful Bladder Syndrome;Interstitial CystitisDrug: Botox;Other: normal salineUniversity of WashingtonPaul G. Allen Family FoundationNot recruiting18 YearsN/AFemale20Phase 4United States
82NCT00086684September 200319 October 2017Effectiveness and Safety Study of Pentosan Polysulfate Sodium for the Treatment of Interstitial CystitisRandomized, Double-Blind, Placebo-Controlled, Parallel Group Evaluation of the Efficacy and Tolerability of Two Different Doses of ELMIRON for the Treatment of Interstitial CystitisInterstitial CystitisDrug: Pentosan polysulfate sodium 100 mg;Drug: PlaceboJohnson & Johnson Pharmaceutical Research & Development, L.L.C.Not recruiting18 YearsN/AAll369Phase 4United States;Canada
83NCT00004316June 199519 February 2015Phase I/II Randomized, Placebo-Controlled Study of Capsaicin for Interstitial Cystitis and Vulvar VestibulitisInterstitial Cystitis;Vulvar DiseasesDrug: capsaicinNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)University of PittsburghNot recruiting18 YearsN/AFemale139Phase 1/Phase 2

先頭へ